Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
Posters
Scientific Publications
Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial
Date : 11/12/2022
Download the poster
Previous Post
December 13, 2022: BFM Business interview of Hervé Affagard - Good Morning Business
Next Post
December 11, 2022: MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting
Close Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
MaaT Pharma dans les médias
MaaT Pharma in the News
Devenez membre du club
Become a member of the club